GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
---|
MIR147B | 33655 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 26323893
|
MIR147B | 33655 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 26323893
|
MIR1976 | 37064 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 26323893
|
MIR1976 | 37064 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 26323893
|
MIR3622A | 38934 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 26323893
|
MIR3622A | 38934 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 26323893
|
MIR424 | 31881 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0064 | 26323893
|
MIR424 | 31881 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0064 | 26323893
|
MIR4730 | 41880 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIR4730 | 41880 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIR6836 | 50067 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIR6836 | 50067 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIR6873 | 50231 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIR6873 | 50231 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIR7152 | 50257 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIR7152 | 50257 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 26323893
|
MIRLET7A1 | 31476 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 26323893
|
MIRLET7A1 | 31476 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 26323893
|
NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.5461 | 26323893
|
NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.5461 | 26323893
|
NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | SFA followed by qPCR | NA | 0.2 | 0.5461 | 21304586
|
POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.6448 | 26323893
|
POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.6448 | 26323893
|
POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | SFA followed by qPCR | NA | 0.2 | 0.6448 | 21304586
|
SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.5695 | 26323893
|
SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.5695 | 26323893
|
SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | SFA followed by qPCR | NA | 0.2 | 0.5695 | 21304586
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.12 | 0.684 | 26323893
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | SFA followed by ALDEFLUOR assay | NA | 0.12 | 0.684 | 21304586
|
ALDH1A2 | 15472 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.12 | 0.0117 | 26323893
|
CD24 | 1645 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | SFA followed by FACs | NA | 0.12 | 0.456 | 21304586
|
CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UT-SCC-9 | NA | SFA followed by FACs | NA | 0.12 | 1 | 21304586
|